Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 134,385 shares were traded during trading, an increase of 19% from the previous session's volume of 112,698 shares.The stock last traded at $10.14 and had previously closed at $10.18.
Analyst Ratings Changes
Separately, Noble Financial began coverage on shares of Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an "outperform" rating for the company.
View Our Latest Research Report on Gyre Therapeutics
Gyre Therapeutics Stock Down 3.8%
The firm's 50 day simple moving average is $8.96 and its two-hundred day simple moving average is $10.49. The stock has a market capitalization of $853.20 million, a P/E ratio of 455.00 and a beta of 1.90.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported $0.03 EPS for the quarter, hitting the consensus estimate of $0.03. The firm had revenue of $22.06 million during the quarter, compared to the consensus estimate of $28.40 million. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.
Institutional Investors Weigh In On Gyre Therapeutics
Hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its position in shares of Gyre Therapeutics by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after buying an additional 913 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Gyre Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company's stock worth $1,386,000 after purchasing an additional 918 shares during the last quarter. Barclays PLC lifted its stake in Gyre Therapeutics by 13.5% during the fourth quarter. Barclays PLC now owns 10,543 shares of the company's stock worth $128,000 after purchasing an additional 1,255 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Gyre Therapeutics by 11.1% in the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company's stock worth $168,000 after purchasing an additional 1,389 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Gyre Therapeutics by 15,083.3% during the 1st quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock valued at $140,000 after purchasing an additional 1,810 shares during the last quarter. 23.99% of the stock is currently owned by institutional investors.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
